Administartive issues

The goal of this observational study is to evaluate the effectiveness of the carnitine-orotate complex and biphenyl dimethyl dicarboxylate in the adjuvant therapy of chronic hepatitis D in real clinical practice: a prospective cohort study

Inclusion Criteria:

• Patients of both sexes aged 18 to 75 years who are citizens of the Republic of Kazakhstan;
• An established diagnosis of CGD (chronic viral hepatitis B with the delta agent);
• Patients who have contraindications to taking peg-INF-alpha2a and/or have failed treatment with peg-INF-alpha2a;
• Compensated liver disease ≤ CPT A (6 points);
• Patients without severe concomitant diseases;
• Patients who do not receive other adjuvant therapy (metabolic therapy drugs, essential phospholipids, ursodeoxycholic acid, glycyrrhizic acid, ademetionine and others);
• Patients who voluntarily signed the informed consent form.

Exclusion Criteria:

• Patients taking COC for more than 4 weeks before inclusion in the study;
• Patients with contraindications to the COC;
• Decompensated liver disease severity class > CPT A6;
• Patients taking peg-IFN-alpha 2a;
• Alcohol abuse according to the AUDIT-c questionnaire;
• Pregnancy and lactation;
• Patients with coinfection with HIV, HCV;
• GFR ≤ 15 ml/min/1.73 m2;
• Exclude patients with significant biochemical activity (ALT, AST more than 10 ULN) and total bilirubin more than 2 norms;
• Patients with other causes of liver damage;
• Drug addict people;
• Malignant formations of the liver and other organs (in history and currently) or a clinically significant increase in alpha-fetoprotein more than 5 times or more;
• Patient takes part in an interventional clinical trial.

Persons aged ≥18 to 75 years inclusive with a diagnosis of chronic hepatitis D who are undergoing outpatient monitoring at the place of residence.